HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jil Sander for men and women

This article was originally published in The Rose Sheet

Executive Summary

New Jil Sander Scent 79 Woman and Jil Sander Scent 79 Man represent at once sophistication and purity - "a paradox held dear to Jil Sander," according to recent release. Jil Sander Scent 79 Woman, "crafted like haute couture clothing" by Symrise's Evelyne Boulanger, contains aldehyde accord, "sparkling" cranberries, white leathers and caramelized wood, "united by the fullness of vetiver," while packaging, designed by Peter Schmidt, is "emblematic of the Jil Sander style" with avant-garde vertical shape that stacks two symmetrical cubes together. Jil Sander Scent 79 Man, the creation of Symrise's Marc Buxton, has a "bold, contrasting personality"; notes include angelica root, clary sage, frankincense, as well as floral notes of jasmine, violet wood and orris concrete "atypical in the men's perfume world." Packaging consists of cube-over-cube structure slipped into black lacquered case with a white logo. Jil Sander Scent 79 Woman is priced at $110 for 4.2-oz. bottle, and Jil Sander Scent 79 Men at $90 for 4.2-oz. bottle. Both fragrances will be available in November exclusively at Neiman Marcus

You may also be interested in...



Dainippon, SanBio Call Time On Stroke Cell Therapy Alliance

Japanese companies agree to discontinue regenerative cell therapy pact after high-profile failure Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.

Strides Targets $200-400m From Generic Injectables In Mid-Term

Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.

Abbott Readying Vildagliptin ER In India Amid Price Competition

Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.
UsernamePublicRestriction

Register

RS015645

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel